https://orcid.org/0000-0003-2996-0235
References
- FDA. Guidance for industry: quality considerations in demonstrating biosimilarity of a therapeutic protein product to a reference product; April 2015.
- Guideline on similar biological medicinal products containing biotechnology –derived proteins as active substance: non-clinical and clinical issues, EMEA/CHMP/BMWP/42832/ 2005 Rev 1; December 2014.
- Brokx S, Scrocchi L, Shah N, et al. A demonstration of analytical similarity comparing a proposed biosimilar pegfilgrastim and reference pegfilgrastim. Biologicals. 2017 Jul;48:28–38.
- Neulasta® (pegfilgrastim). Prescribing information. Amgen Inc. November 21, 2018. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125031s193lbl.pdf.
- Roberts MJ, Bentley MD, Harris JM. Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev. 2002 Jun 17;54(4):459–476.
- Mehta HM, Malandra M, Corey SJ. G-CSF and GM-CSF in neutropenia. J Immunol. 2015 Aug 15;195(4):1341–1349.
- Souza LM, Boone TC, Gabrilove J, et al. Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. Science. 1986 Apr 4;232(4746):61–65.
- Kuan JW, Su AT, Leong CF. Pegylated granulocyte-colony stimulating factor versus non-pegylated granulocyte-colony stimulating factor for peripheral blood stem cell mobilization: a systematic review and meta-analysis. J Clin Apher. 2017 Dec;32(6):517–542.
- Pineda C, Castañeda Hernández G, Jacobs IA, et al. Assessing the immunogenicity of biopharmaceuticals. BioDrugs. 2016 Jun;30(3):195–206.
- Gupta S, Indelicato SR, and Jethwa V, et al. Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. J Immunol Methods. 2007 Apr 10;321(1–2):1–18.
- Gupta S, Devanarayan V, and Finco D, et al. Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics. J Pharm Biomed Anal. 2011 Jul 15;55(5):878–888.
- Zou L, Buchner A, Roberge M, et al. Immunogenicity assessment of lipegfilgrastim in patients with breast cancer receiving chemotherapy. J Immunol Res. 2016;2016:9248061.
- van Schouwenburg PA, Bartelds GM, Hart MH, et al. A novel method for the detection of antibodies to Adalimumab in the presence of drug reveals “hidden” immunogenicity in rheumatoid arthritis patients. J Immunol Methods. 2010;362(1–2):82–88.
- Guideline on immunogenicity assessment of therapeutic proteins, EMEA/CHMP/BMWP/14327/2006 Rev 1; May 2017.
- FDA. Guidance for industry: immunogenicity testing of therapeutic protein products —developing and validating assays for anti-drug antibody detection.
- Singh I, Attrey A, Garg A, et al. Single-dose pharmacokinetics, pharmacodynamics and immunogenicity, and multiple-dose immunogenicity of INTP5 (Pegfilgrastim Biosimilar) versus reference pegfilgrastim in healthy subjects. Clin Drug Investig. 2021 Jan;41(1):29–42.
- Shankar G, Devanarayan V, and Amaravadi L, et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J Pharm Biomed Anal. 2008 Dec 15;48(5):1267–1281.
- Devanarayan V, Smith WC, and Brunelle RL, et al. Recommendations for systematic statistical computation of immunogenicity cut points. Aaps J. 2017 Sep;19(5):1487–1498.
- Bennett CL, Luminari S, Nissenson AR, et al. Pure red-cell aplasia and epoetin therapy. N Engl J Med. 2004;351:1403–1408.